The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
Status:
RECRUITING
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
Phase:
PHASE3
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Treatments:
fructus schizandrae, radix ginseng, radix ophiopogonis drug combination schizandrin